US 12,453,712 B2
Antitumoral use of cabazitaxel
Sunil Gupta, Lexington, MA (US)
Assigned to Sanofi Mature IP, Gentilly (FR)
Filed by Sanofi Mature IP, Gentilly (FR)
Filed on Jul. 20, 2023, as Appl. No. 18/224,122.
Application 18/224,122 is a continuation of application No. 18/073,982, filed on Dec. 2, 2022, abandoned.
Application 18/073,982 is a continuation of application No. 17/729,371, filed on Apr. 26, 2022, abandoned.
Application 17/729,371 is a continuation of application No. 16/931,802, filed on Jul. 17, 2020, abandoned.
Application 16/931,802 is a continuation of application No. 16/743,411, filed on Jan. 15, 2020, granted, now 10,716,777, issued on Jul. 21, 2020.
Application 16/743,411 is a continuation of application No. 15/627,962, filed on Jun. 20, 2017, granted, now 10,583,110, issued on Mar. 10, 2020.
Application 15/627,962 is a continuation of application No. 14/575,566, filed on Dec. 18, 2014, abandoned.
Application 14/575,566 is a continuation of application No. 13/456,720, filed on Apr. 26, 2012, granted, now 8,927,592, issued on Jan. 6, 2015.
Application 13/456,720 is a continuation of application No. PCT/IB2010/054866, filed on Oct. 27, 2010.
Claims priority of provisional application 61/389,969, filed on Oct. 5, 2010.
Claims priority of provisional application 61/383,933, filed on Sep. 17, 2010.
Claims priority of provisional application 61/369,929, filed on Aug. 2, 2010.
Claims priority of provisional application 61/355,834, filed on Jun. 17, 2010.
Claims priority of provisional application 61/355,888, filed on Jun. 17, 2010.
Claims priority of provisional application 61/293,903, filed on Jan. 11, 2010.
Claims priority of provisional application 61/256,160, filed on Oct. 29, 2009.
Prior Publication US 2024/0139146 A1, May 2, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/337 (2006.01); A61K 31/164 (2006.01); A61K 31/56 (2006.01); A61K 31/573 (2006.01); A61K 38/19 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/337 (2013.01) [A61K 31/164 (2013.01); A61K 31/56 (2013.01); A61K 31/573 (2013.01); A61K 38/193 (2013.01); A61K 45/06 (2013.01)] 13 Claims
 
1. A method of increasing survival comprising administering to a patient in need thereof a dose of 15 to 25 mg/m2 of cabazitaxel, or a hydrate or solvate thereof, in combination with an antihistamine, wherein the antihistamine is administered to the patient prior to administering the dose of cabazitaxel, or a hydrate or solvate thereof, and wherein said patient has castration resistant metastatic prostate cancer that has progressed during or after treatment with docetaxel.